Ocuphire Pharma Investor Day Presentation Deck
P
95
你好
VEGA-1 (Post-Hoc): Efficacy Across Presbyopia Ages
Nyxol Highest Efficacy in Young Presbyopes as Expected; Also Efficacy Seen in Older Presbyopes
Percent of Subjects (%)
VEGA-1 Phase 2 Trial
Percent of Subjects With 15 Letter Improvement From Baseline in Photopic DCNVA at 0
Minutes for Nyxol and Placebo Treated Subjects by Age Group 40-54 yrs and 55-64 yrs
40%
35%
30%
25%
20%
15%
10%
5%
0%
Placebo Nyxol
20%
n=48
Age 40-54
36%
n=42
Age Groups
0%
n=26
p<0.05
Age 55-64
Note: Trend toward statistical significance p=0.15 in age 40-54; larger sample size for all arms planned in Phase 3 program
Source: VEGA-1 TLR Table 14.2.1.7.1 & 14.2.1.7.2 Percent of Subjects with Improvement in Photopic DCNVA by Age Group (PP Population)
23%
n=31
Nyxol
demonstrated
efficacy in 55
to 64 age
group and
Efficacy seen
at 12 hours
Ocuphire
PHARMAView entire presentation